Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
A triple combination targeting epigenetic dysregulation and apoptotic resistance, comprising iadademstat (LSD1 inhibitor), azacitidine (a hypomethylating agent), and venetoclax (a BCL-2 inhibitor), is under investigation in a phase I trial for acute myeloid leukemia (NCT06357182)
It has not been evaluated by the Food and Drug Administration (FDA) and is not intended to diagnose, treat, cure, or prevent any disease or medical condition
Detailed Description BPC-157 , also known as Body Protection Compound-157, is a synthetic pentadecapeptide (15 amino acids) derived from a naturally occurring protein in gastric juice
Why our customers love us
Advanced Analytical Verification: Every batch is validated through HPLC and Mass Spectrometry (MS) to confirm chemical identity and ensure precise peptide purity
US$ 27.26
US$ 22.27
US$ 20.96
US$ 23.40
